Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Updated Data With Oral Proteasome Inhibitor MLN9708 Reported In Newly Diagnosed Multiple Myeloma Patients
12/10/2013 10:29:43 AM
NEW ORLEANS & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The investigators reported a combined complete response and very good partial response (CR+VGPR) rate of 76 percent (46/62) and a 94 percent overall response rate (ORR; 58/62 = partial response). Stringent complete response (sCR) was reached in 75 percent of patients that attained CR. Overall, drug-related serious adverse events (SAEs) were reported in 28 percent of patients (18/64), and drug-related grade 3 adverse events (AEs) in 58 percent of patients (37/64). There were no drug-related grade 4 AEs. These data were presented today at the 55th American Society of Hematology (ASH) annual meeting held December 7-10 in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by